A Phase 1 interventional study of Atazanavir+Ritonavir+Tenofovir and Atazanavir+Ritonavir+Tenofovir+Famotidine in HIV Infections, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-04-08.
Sponsored by Bristol-Myers Squibb · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing atazanavir in HIV Infections — none open to participants now, 1 under way, 1 of them phase 3. atazanavir · HIV Infections.
Among the 73 studies testing atazanavir in HIV Infections, this one is the 45th largest by enrollment of the 69 interventional ones that give a count, is one of 12 that started in 2006, is one of 16 in phase 1, and was the 35th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →None of the 73 studies testing atazanavir in HIV Infections is open now. The open studies under HIV Infections, anywhere →
atazanavir: first FDA approval 2003 (REYATAZ), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 10 · Phase 3 20 · Phase 4 25
First in 2000; this study’s year is marked. 12 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 55 across the 69 interventional studies. Of the 68 that completed or were terminated, 25 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 73 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
77 studies in HIV Infections by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 73 finished, 9 (12%) have results posted.
Among the 77 studies in HIV Infections by Bristol-Myers Squibb, this one is the 31st largest by enrollment of the 48 interventional ones that give a count, is one of 10 that started in 2006, is one of 16 in phase 1, and was the 68th registered.
Bristol-Myers Squibb’s HIV Infections studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 73 studies testing atazanavir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 77 in HIV Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical research study is to assess the pharmacokinetics of atazanavir, identifying one or more dosing regimens of atazanavir/ritonavir/tenofovir when dosed with famotidine results in atazanavir exposures similar to those when atazanavir/ritonavir/tenofovir 300/100/300 mg is dosed without famotidine in healthy subjects.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Atazanavir+Ritonavir+Tenofovir
Drug: Atazanavir+Ritonavir+Tenofovir+Famotidine
Drug: Atazanavir+Ritonavir+Tenofovir+Famotidine
Drug: Atazanavir+Ritonavir+Tenofovir+Famotidine
Drug: Atazanavir+Ritonavir+Tenofovir+Famotidine
Drug pages: Atazanavir · Ritonavir · Tenofovir
Cap/Cap/Tablet, Oral, 300/100/300 mg, QAM/QAM/QAM, 10 days.
Also known as: Abilify
Drug pages: Atazanavir · Ritonavir · Tenofovir · Famotidine
Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 coadmin, 7 days.
Also known as: Abilify
Drug pages: Atazanavir · Ritonavir · Tenofovir · Famotidine
Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 2 hr post, 7 days.
Also known as: Abilify
Drug pages: Atazanavir · Ritonavir · Tenofovir · Famotidine
Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/QPM 12 hr post, 7 days.
Also known as: Abilify
Drug pages: Atazanavir · Ritonavir · Tenofovir · Famotidine
Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/Q12 2 hr post,7 days.
Also known as: Abilify
Assess PK of ATV, identifying dosing regimens of ATV/RTV/TDF when dosed with FAM that result in ATV exposures similar to ATV/RTV/TDF 300/100/300 mg with and without FAM.
Assess PK , safety, and tolerability of ATV/RTV/TDF with and without FAM.
The record gives a start of Apr 2006, a primary completion of Jun 2006 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Atazanavir · Ritonavir · Tenofovir · Famotidine